Besremi (Ropeginterferon Alfa-2b) can be difficult to find. Learn why this polycythemia vera treatment is hard to get and what you can do about it in 2026.
If you've been prescribed Besremi (Ropeginterferon Alfa-2b-njft) for polycythemia vera and you're struggling to get your hands on it, you're not alone. Many patients across the country have reported difficulty filling their Besremi prescriptions, and the frustration is real — especially when you're dealing with a serious blood disorder that needs consistent treatment.
In this article, we'll break down exactly why Besremi is so hard to find in 2026, what's driving the supply issues, and what steps you can take to get the medication you need.
Besremi is the brand name for Ropeginterferon Alfa-2b-njft, a pegylated interferon therapy made by PharmaEssentia Corporation. It was FDA-approved in November 2021 as the first interferon therapy specifically indicated for the treatment of polycythemia vera (PV) in adults.
Polycythemia vera is a rare blood cancer where your bone marrow makes too many red blood cells. This thickens your blood and increases the risk of dangerous blood clots, heart attack, and stroke. Besremi works by targeting the underlying disease — specifically the JAK2 V617F mutant clone — rather than just managing symptoms.
Besremi is given as a subcutaneous injection every two weeks, and the NCCN Clinical Practice Guidelines recommend it as a preferred first-line cytoreductive treatment option for certain patients with PV. For more details on what this medication does, check out our guide on what Besremi is and how it works.
Besremi isn't something you pick up at your local Walgreens or CVS. It's a specialty biologic medication that must be prescribed through specialty pharmacies and shipped directly to your home. This means it's not sitting on shelves at retail pharmacies, and the distribution network is much narrower than for common prescriptions.
Specialty pharmacies have specific storage and handling requirements for biologics like Besremi, which limits how many pharmacies can carry it. If your specialty pharmacy runs into a supply issue, you may face delays that wouldn't happen with a more widely distributed drug.
One of the biggest factors making Besremi harder to find in 2025 and 2026 is the ongoing shortage of Pegasys (Peginterferon Alfa-2a), another interferon therapy that has been widely used off-label for polycythemia vera.
The Pegasys shortage began in 2024 and has been expected to continue through mid-2025 or beyond. As Pegasys became unavailable, the NCCN updated its guidelines in January 2025 to recommend substituting Besremi for patients who can no longer get Pegasys. This sudden influx of patients switching to Besremi has put significant pressure on the supply chain.
To make matters more challenging, non-pegylated Interferon Alpha-2a was discontinued in the United States back in 2021, which means Besremi is essentially the only FDA-approved interferon option left for PV patients.
Besremi is a biologic medication, which means it's produced using living cells rather than chemical synthesis. Manufacturing biologics is inherently more complex, time-consuming, and expensive than producing traditional small-molecule drugs. Any disruption in the manufacturing process — even minor ones — can lead to supply constraints that take weeks or months to resolve.
PharmaEssentia has been working to scale up production to meet growing demand, but ramping up biologic manufacturing isn't as simple as flipping a switch.
Even when Besremi is available from the manufacturer, getting it into your hands can be slowed down by insurance hurdles. Most insurance plans require prior authorization for Besremi, and some may require step therapy — meaning you need to try and fail on a less expensive medication like Hydroxyurea before they'll approve Besremi.
These administrative delays can add days or weeks to the process, making it feel like the drug is impossible to find when it's really the paperwork holding things up. For tips on navigating the cost side, see our article on how to save money on Besremi.
One of the fastest ways to find out where Besremi is in stock is to use Medfinder. Medfinder helps you search specialty pharmacies that carry Besremi and can show you which ones have it available right now.
Your hematologist or hematology-oncologist's office likely has relationships with specialty pharmacies and may be able to expedite the process. Let them know you're having trouble, and ask if they can contact the pharmacy on your behalf or explore alternative distribution channels.
PharmaEssentia offers a patient support program called PharmaEssentia SOURCE that can help with access issues. They can assist with insurance navigation, prior authorization support, and connecting you with pharmacies that have stock. Call them at 1-833-546-7473.
If you simply cannot get Besremi and your condition needs immediate management, talk to your doctor about alternatives like Hydroxyurea or Jakafi (Ruxolitinib). These work differently but can help manage PV while you wait for Besremi to become available.
If you're facing a gap in your Besremi supply, do not just stop treatment without speaking to your hematologist. Suddenly stopping interferon therapy can cause your blood counts to rebound, increasing your risk of blood clots and other complications. Your doctor can advise you on the safest approach.
Finding Besremi in 2026 can be a challenge, but it's not impossible. The combination of specialty pharmacy distribution, the Pegasys shortage driving up demand, complex biologic manufacturing, and insurance hurdles all contribute to the difficulty. But by using tools like Medfinder, working closely with your hematologist, and contacting PharmaEssentia SOURCE, you can improve your chances of getting the medication you need.
For more help locating Besremi, check out our guide on how to find Besremi in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
